We are breaking technological barriers in the way of medical diagnostics

Prostate cancer diagnostic needs innovation

Global Problem

Benefit to the World

Global Problem

Prostate cancer is the 2nd most common male cancer in the world.

In 2020, there were more than 1.4 million new cases and over 370 thousand patients died of prostate cancer.

Many lives could be saved if the cancer had been diagnosed at early stage.

Unfortunately, the current prostate cancer diagnostics are inaccurate, invasive and require specialised equipment. These limitations result in cancer being diagnosed too late to allow effective treatment.

Learn more

Swiss Solution

Benefit to the World

Global Problem

We believe that prostate cancer diagnostic can be and should be improved.

MUGENBIO develops the next-generation medical diagnostic platform, which integrates three key innovations:

Nanofluidic device for optimised liquid biopsy acquisition

Ultra-senstive method for quantification of multiple biomarkers

AI data analytics for more accurate prostate cancer detection and staging

Benefit to the World

MUGENBIO's innovations will improve prostate cancer diagnostic and bring a number of benefits to patients, including:

More sensitive and specific prostate cancer diagnosis

More of aggressive tumors diagnosed early

Higher efficacy of prostate cancer treatment

Less unnecessary prostate biopsies

Hundreds of thousands of lives saved annually worldwide

We are breaking technological barriers in the way of medical diagnostics

We are breaking technological barriers in the way of medical diagnostics

Prostate cancer diagnostic needs innovation

Global Problem

Benefit to the World

Global Problem

Swiss Solution

Benefit to the World

Global Problem

Benefit to the World

Benefit to the World

Benefit to the World

This website uses cookies.